DNA Link Inc (127120) - Total Liabilities

Latest as of March 2026: ₩53.95 Billion KRW ≈ $36.56 Million USD

Based on the latest financial reports, DNA Link Inc (127120) has total liabilities worth ₩53.95 Billion KRW (≈ $36.56 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

DNA Link Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how DNA Link Inc's total liabilities have evolved over time, based on quarterly financial data. See DNA Link Inc (127120) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

DNA Link Inc Competitors by Total Liabilities

The table below lists competitors of DNA Link Inc ranked by their total liabilities.

Company Country Total Liabilities
Valeura Energy Inc
TO:VLE
Canada CA$429.55 Million
R&S GROUP HOLDING AG
SW:RSGN
Switzerland CHF262.41 Million
Osisko Development Corp
V:ODV
Canada CA$616.83 Million
Dongfeng Electronic Technology Co Ltd
SHG:600081
China CN¥4.22 Billion
Ads Tec Energy PLC
NASDAQ:ADSE
USA $101.03 Million
engcon AB Cl B
ST:ENGCON-B
Sweden Skr653.00 Million
Hangzhou Biotest Biotech Co Ltd
SHG:688767
China CN¥121.73 Million
Lsb Industries Inc
NYSE:LXU
USA $648.41 Million

Liability Composition Analysis (2011–2025)

This chart breaks down DNA Link Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 127120 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.72 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.60 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how DNA Link Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for DNA Link Inc (2011–2025)

The table below shows the annual total liabilities of DNA Link Inc from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩54.44 Billion
≈ $36.90 Million
+85.46%
2024-12-31 ₩29.36 Billion
≈ $19.89 Million
+135.23%
2023-12-31 ₩12.48 Billion
≈ $8.46 Million
-20.09%
2022-12-31 ₩15.62 Billion
≈ $10.58 Million
+89.40%
2021-12-31 ₩8.25 Billion
≈ $5.59 Million
-40.42%
2020-12-31 ₩13.84 Billion
≈ $9.38 Million
-14.77%
2019-12-31 ₩16.24 Billion
≈ $11.00 Million
+5.02%
2018-12-31 ₩15.46 Billion
≈ $10.48 Million
+996.65%
2017-12-31 ₩1.41 Billion
≈ $955.48K
-94.14%
2016-12-31 ₩24.04 Billion
≈ $16.29 Million
+11.69%
2015-12-31 ₩21.53 Billion
≈ $14.59 Million
+68.92%
2014-12-31 ₩12.74 Billion
≈ $8.64 Million
+3.34%
2012-12-31 ₩12.33 Billion
≈ $8.36 Million
+37.43%
2011-12-31 ₩8.97 Billion
≈ $6.08 Million
--

About DNA Link Inc

KQ:127120 Korea Biotechnology
Market Cap
$843.98 Million
₩1.25 Trillion KRW
Market Cap Rank
#9832 Global
#270 in Korea
Share Price
₩36100.00
Change (1 day)
+1.12%
52-Week Range
₩9260.00 - ₩48900.00
All Time High
₩48900.00
About

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more